Ustekinumab as induction and maintenance therapy for ulcerative colitis - national extended follow-up and a review of the literature

CONCLUSION: For moderate-to-severe UC in Australia, ustekinumab maintained efficacy beyond 3 years with a high persistence rate and no new safety signals.TRIAL REGISTRATION: The trial is registered at ANZCTR (identifier: ACTRN12622001332718).PMID:37909484 | DOI:10.1080/14740338.2023.2278686

Source: Expert Opinion on Drug Safety - November 1, 2023 Category: Drugs & Pharmacology Authors: J D Chetwood S Gupta K Subramaniam P De Cruz G Moore Y K An S J Connor M Kermeen S Paramsothy R W Leong Source Type: research